Generex Biotechnology Corporation  

(Public, OTCMKTS:GNBT)   Watch this stock  
0.0000 (0.00%)
Oct 2 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.01 - 0.01
52 week 0.01 - 0.04
Open 0.01
Vol / Avg. 0.00/2.40M
Mkt cap 8.77M
P/E 24.32
Div/yield     -
EPS 0.00
Shares 819.94M
Beta 0.86
Inst. own 0%

Key stats and ratios

Q2 (Apr '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -174.73% -0.03%
Return on average equity - -
Employees 8 -
CDP Score - -


33 Harbour Sq Suite 202
+1-416-3642551 (Phone)

Website links


Generex Biotechnology Corporation is a Canada-based engaged primarily in the research and development of drug delivery systems and technologies. The Company’s primary focus is on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through its wholly owned subsidiary, Antigen, it has expanded its focus to include immunomedicines incorporating vaccine formulations. The Company has identified several molecule drugs as possible candidates for development, including estrogen, heparin, monoclonal antibodies, human growth hormone and fertility hormones, but has focused its development efforts primarily on one pharmaceutical product, Generex Oral-lyn an insulin formulation administered as a fine spray into the oral cavity using its hand-held aerosol spray applicator known as RapidMist.

Officers and directors

Mark A. Fletcher Esq President, Chief Executive Officer, General Counsel, Director
Stephen Fellows Chief Financial Officer
David A. Brusegard Ph.D. Chief Operating Officer, Secretary
Eric von Hofe Ph.D. Director
Age: 59
James H. Anderson Jr,M.D. Independent Director
Age: 68
Brian T. McGee Independent Director
Age: 53